Clinical Trials
44 trialsTargeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)
M.D. Anderson Cancer Center
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
National Cancer Institute (NCI)
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma
Shandong Cancer Hospital and Institute
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
University of California, San Francisco
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
Rutgers, The State University of New Jersey
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
M.D. Anderson Cancer Center
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
Rutgers, The State University of New Jersey
Charlie-2
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent and Metastatic Cervical Cancer, Vulvar Cancer and Vaginal Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer
Zhongnan Hospital
Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy
Lipomedix Pharmaceuticals Inc.
POD1UM-204
Incyte Corporation
ARTIST
Artios Pharma Ltd
PAVO
Tempus AI
Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy
Regeneron Pharmaceuticals
Personalized Ultra-fractionated Stereotactic Adaptive Radiotherapy for Metastatic Cervical Cancer
University of Texas Southwestern Medical Center
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Elevation Oncology
Study of AK112 in the Treatment of Advanced Gynecological Tumors
Akeso
HPV-VIM
Baylor College of Medicine
Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.
Nykode Therapeutics ASA
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers
M.D. Anderson Cancer Center
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Memorial Sloan Kettering Cancer Center
Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer
Nykode Therapeutics ASA
LODESTAR
pharmaand GmbH
ENDOPIK
ARCAGY/ GINECO GROUP
Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer
Canadian Cancer Trials Group
Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma
Eastern Cooperative Oncology Group
CABOCOL-01
Centre Francois Baclesse
ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma
National Institutes of Health Clinical Center (CC)
Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer
Catalysis SL
Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers
Masonic Cancer Center, University of Minnesota
NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018)
AGC Biologics S.p.A.
A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer
Pfizer
A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers
Ipsen
NGR018
AGC Biologics S.p.A.
ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment
Sanofi
Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases
National Institutes of Health Clinical Center (CC)
NRR
UNC Lineberger Comprehensive Cancer Center
Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain
National Institutes of Health Clinical Center (CC)
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
Merrimack Pharmaceuticals
IPHC
Wuhan University